"Global cancer statistics 2022" based on the latest GLOBCAN data from the International Agency for Research on Cancer (IARC) was recently released, providing a systematic analysis of the incidence and mortality of 36 types of cancer across 185 countries worldwide. The international burden of cancer is expected to continue to increase over the next 30 years, posing a severe public health and social challenge for many countries, including China. This article offers a key point interpretation of the "Global cancer statistics 2022", focusing on the evolution of cancer epidemiology and future development trends. The aim is to broaden the international perspective on cancer prevention and treatment, with the hope of providing reference and guidance for cancer prevention and treatment efforts in our country.
目的探討單腔氣管內插管保留自主呼吸的靜脈全身麻醉下小兒胸腔鏡手術的可行性及安全性。 方法選取鄭州大學第一附屬醫院胸外科2012年2～12月采用單腔氣管內插管保留自主呼吸行靜脈全身麻醉下胸腔鏡手術治療的14例患兒作為試驗組，男9例、女5例，年齡4～9歲；選取2010年5月至2011年10月采用常規雙腔氣管內插管全身麻醉下胸腔鏡手術治療的20例小兒患者作為對照組，男13例、女7例，年齡3～10歲。比較兩組手術時間、術中失血量、術畢至拔管時間、住院費用、住院時間及術后并發癥發生率等指標。 結果兩組患兒手術均順利，無術中術后死亡。試驗組和對照組患兒平均手術時間[（85.7±16.9）min vs.（83.5±16.5）]及術中失血量[（90.0±55.0）ml vs.（85.0±50.0）ml]差異無統計學意義（P>0.05）。試驗組的術畢至拔管時間[（0.5±0.1）min vs.（8.3±1.4）min]、住院費用[（24.3±4.7）千元vs.（27.8±5.3）千元]、住院時間[（6.6±0.9）d vs.（12.7±3.2）d]、術后并發癥發生率（7.1%vs.25.0%）都顯著短或少于對照組（P < 0.05）。 結論單腔氣管內插管保留自主呼吸靜脈全身麻醉下小兒胸腔鏡手術治療小兒胸部疾病具有一定的安全性及可行性。